Goldman Sachs’s Ascendis Pharma A/S ASND Stock Holding History

Goldman Sachs’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,300	Closed	-$1.65M	–	6433
2025 Q3	$1.65M	Sell	8,300 -2,100	-20%	-$392K	﹤0.01%	4642
2025 Q2	$1.8M	Buy	+10,400	New	+$1.69M	﹤0.01%	4259
2024 Q4	–	Sell	-45,000	Closed	-$6.72M	–	6017
2024 Q3	$6.72M	Buy	45,000 +35,900	+395%	+$4.85M	﹤0.01%	3095
2024 Q2	$1.24M	Buy	+9,100	New	+$1.24M	﹤0.01%	4302
2023 Q2	–	Sell	-27,000	Closed	-$2.89M	–	5737
2023 Q1	$2.89M	Buy	27,000 +20,400	+309%	+$2.33M	﹤0.01%	3552
2022 Q4	$806K	Sell	6,600 -68,400	-91%	-$7.94M	﹤0.01%	4572
2022 Q3	$7.74M	Buy	+75,000	New	+$7.11M	﹤0.01%	2746
2020 Q4	–	Sell	-20,000	Closed	-$3.09M	–	5471
2020 Q3	$3.09M	Buy	+20,000	New	+$2.87M	﹤0.01%	3261

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs's ASND Position: Q1 2026 in Review

Goldman Sachs reduced its Ascendis Pharma A/S (ASND) stake by 5.1% in Q1 2026, selling an estimated $6.84M and leaving 566,192 shares worth $130M. The position accounts for 0.01% of the portfolio, ranked #886.

Goldman Sachs first reported a position in ASND in Q4 2017 and has held it in 34 quarters since. The position peaked at $308M in Q2 2022. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Goldman Sachs held 566,192 shares of Ascendis Pharma A/S worth $130M as of Q1 2026.
Goldman Sachs sold 30,511 Ascendis Pharma A/S shares in Q1 2026, an estimated $6.84M.
Ascendis Pharma A/S made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #886 holding.
Goldman Sachs first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 34 quarters since.
Goldman Sachs's Ascendis Pharma A/S position peaked at $308M in Q2 2022.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.